Abstract:BackgroundFollistatin (FST) is an intrinsic inhibitor of activin, a member of the transforming growth factor-β superfamily of ligands. The prognostic value of FST and its family members, the follistatin-like (FSTL) proteins, have been studied in various cancers. However, these studies, as well as limited functional analyses of the FSTL proteins, have yielded conflicting results on the role of these proteins in disease progression. Furthermore, very few have been focused on FST itself. We assessed whether FST may be a suppressor of tumorigenesis and/or metastatic progression in breast cancer.MethodsUsing publicly available gene expression data, we examined the expression patterns of FST and INHBA, a subunit of activin, in normal and cancerous breast tissue and the prognostic value of FST in breast cancer metastases, recurrence-free survival, and overall survival. The functional effects of activin and FST on in vitro proliferation, migration, and invasion of breast cancer cells were also examined. FST overexpression in an autochthonous mouse model of breast cancer was then used to assess the in vivo impact of FST on metastatic progression.ResultsExamination of multiple breast cancer datasets revealed that FST expression is reduced in breast cancers compared with normal tissue and that low FST expression predicts increased metastasis and reduced overall survival. FST expression was also reduced in a mouse model of HER2/Neu-induced metastatic breast cancer. We found that FST blocks activin-induced breast epithelial cell migration in vitro, suggesting that its loss may promote breast cancer aggressiveness. To directly determine if FST restoration could inhibit metastatic progression, we transgenically expressed FST in the HER2/Neu model. Although FST had no impact on tumor initiation or growth, it completely blocked the formation of lung metastases.ConclusionsThese data indicate that FST is a bona fide metastasis suppressor in this mouse model and support future efforts to develop an FST mimetic to suppress metastatic progression.

The Emerging Role of Follistatin under Stresses and Its Implications in Diseases

Progress on Inhibin,Activin and Follistatin

The Reign of Follistatin in Tumors and Their Microenvironment: Implications for Drug Resistance

FSTL1: A double-edged sword in cancer development

Follistatin‐like Protein 1 (FSTL1) Promotes Chondrocyte Expression of Matrix Metalloproteinase and Inflammatory Factors Via the NF‐κB Pathway

Local versus systemic control of bone and skeletal muscle mass by components of the transforming growth factor-β signaling pathway

Nucleolar Follistatin Promotes Cancer Cell Survival under Glucose-deprived Conditions Through Inhibiting Cellular Rrna Synthesis*

FSTL1 promotes growth and metastasis in gastric cancer by activating AKT related pathway and predicts poor survival

Deficiency of Follistatin-Like Protein 1 Accelerates the Growth of Breast Cancer Cells at Lung Metastatic Sites.

Follistatin Like Protein-1 Modulates Macrophage Polarization and Aggravates Dextran Sodium Sulfate-Induced Colitis.

Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer

Follistatin-like 1 (FSTL1) interacts with Wnt ligands and Frizzled receptors to enhance Wnt/β-catenin signaling in obstructed kidneys in vivo

Follistatin-Like 1 Attenuates Ischemia/Reperfusion Injury in Cardiomyocytes via Regulation of Autophagy.

Follistatin-like protein 1 modulates IL-17 signaling via IL-17RC regulation in stromal cells

Increased Expression of Follistatin in Breast Cancer Reduces Invasiveness and Clinically Correlates with Better Survival.

Electrostimulated bone marrow human mesenchymal stem cells produce follistatin

Tumor suppressor effect of follistatin-like 1 in ovarian and endometrial carcinogenesis: a differential expression and functional analysis.

Follistatin-like 1 (fstl1) is a Bone Morphogenetic Protein (BMP) 4 Signaling Antagonist in Controlling Mouse Lung Development.

Novel Roles of Follistatin/Myostatin in Transforming Growth Factor-β Signaling and Adipose Browning: Potential for Therapeutic Intervention in Obesity Related Metabolic Disorders

Angiocrine FSTL1 (Follistatin-Like Protein 1) Insufficiency Leads to Atrial and Venous Wall Fibrosis Via SMAD3 Activation

Identification and Characterization of Follistatin As a Novel Angiogenin-Binding Protein